Core Insights - Microbix Biosystems Inc. and EMQN CIC have launched a program to enhance the identification of patients with gene variants affecting the metabolism of Clopidogrel, a widely prescribed antiplatelet drug [1][2] Group 1: EQA Program Details - The new External Quality Assessment (EQA) program aims to ensure proficiency in Point-of-Care Tests (POCTs) that identify three gene variants of the Cytochrome P450 CYP2C19 enzyme, which are critical for determining appropriate Clopidogrel dosing [2][4] - Over 20% of individuals carry these gene variants, which can lead to either overdosing or underdosing of Clopidogrel, posing significant health risks [2][3] Group 2: Market Context - Clopidogrel is prescribed to over 15 million patients annually in the U.S. alone, indicating a substantial market for pharmacogenomic testing to optimize treatment and minimize risks associated with improper dosing [3] - The EQA program will provide participants with three samples every two months, totaling 18 samples per year, to ensure ongoing accuracy in genetic testing [4] Group 3: Company Contributions - Microbix is supplying quality assessment products (QAPs™) for the EQA program, which will assist in evaluating the accuracy of genetic tests and support safe prescription practices [4][5] - The collaboration with EMQN and Copan aims to enhance the quality of genetic testing, with Microbix expanding its role in the field of pharmacogenomics alongside its established presence in infectious diseases and oncology [5][7] Group 4: Company Background - Microbix Biosystems Inc. is a life sciences innovator with over 120 employees, generating revenues of approximately C$2.0 million or more per month, and is involved in manufacturing critical ingredients for the global diagnostics industry [7][8] - The company is ISO 9001 & 13485 accredited and has a presence in over 30 countries, supported by a network of international distributors [8]